Press Releases from THELANSIS KNOWLEDGE PARTNERS LLP (57 total)
Metastatic Colorectal Cancer (mCRC) in 2026: Emerging Therapeutic Landscape, Nov …
Science is advancing, but the unmet need is not disappearing. And for pharma and biotech strategists, the window to act is now.
The Scale of the…
Alzheimer's Disease in 2026: A Field at Inflection & the Strategic Commercial Qu …
Alzheimer's Disease has long been the most frustrating frontier in medicine, a condition affecting tens of millions of people worldwide, draining trillions of dollars from…
Niemann-Pick Disease Market Outlook & Forecast: Advancing Therapeutics, Expandin …
Executive Summary
The global Niemann-Pick Disease (NPD) landscape is entering a transformative phase as advancements in disease-modifying therapies, improved diagnostic pathways, and increasing investment in rare…
Hunter Syndrome (MPS II) Market Outlook & Forecast: Gene Therapy Innovation, Exp …
Executive Summary
The treatment landscape for Hunter Syndrome (Mucopolysaccharidosis Type II, MPS II) is entering one of its most transformative phases in decades. While enzyme replacement…
Glioblastoma Market Outlook & Forecast: Precision Neuro-Oncology, Emerging Thera …
Executive Summary
The treatment landscape for Glioblastoma (GBM) is entering a pivotal phase. Despite remaining one of the most aggressive and difficult-to-treat primary brain tumors, rapid…
Autism Spectrum Disorder (ASD): The Next Frontier in Drug Development Lies Beyon …
Thelansis launches its Autism Spectrum Disorder (ASD) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026, providing strategic intelligence on the evolving…
Amyotrophic Lateral Sclerosis (ALS) Emerging Therapies Report 2026: How Advanced …
For decades, Amyotrophic Lateral Sclerosis (ALS) has remained one of the most devastating neurodegenerative diseases, characterized by rapid progression, irreversible motor neuron loss, and limited…
Osteosarcoma Faces a Decades-Long Treatment Stagnation - New Thelansis Report Ma …
Thelansis Knowledge Partners releases its 2026 Osteosarcoma: Emerging Therapy, Unmet Needs and TPP Insights Report, a comprehensive intelligence resource for biopharma leaders navigating one of…
Recurrent Respiratory Papillomatosis Market Outlook & Forecast: Emerging HPV-Tar …
Thelansis unveils its latest Recurrent Respiratory Papillomatosis (RRP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036), providing a comprehensive analysis of patient populations,…
Charcot-Marie-Tooth (CMT) Market Outlook & Forecast: Advancing Pipelines, Geneti …
Executive Summary
Charcot-Marie-Tooth (CMT) disease is one of the most prevalent inherited neurological disorders globally, yet it remains one of the most underserved. Affecting nearly 2.6…
CIPN Market Outlook & Forecast: Rising Cancer Survivorship, Growing Unmet Needs …
Executive Summary
Chemotherapy-Induced Peripheral Neuropathy (CIPN) remains one of the most common and debilitating complications of cancer treatment, affecting millions of patients receiving taxanes, platinum-based therapies,…
Netherton Syndrome Market Poised for Robust Growth Through 2036 as Disease-Modif …
Thelansis has published a comprehensive new report on the Netherton Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast (2026-2036). This report delivers an end-to-end…
Thelansis Launches EpiLansis: An AI-Powered, Cloud-Based Epidemiology and Market …
EpiLansis delivers real-time epidemiology intelligence, patient journey analytics, and disease burden insights across 450+ indications and 30+ global markets, compressing research timelines from weeks to…
Rheumatoid Arthritis Emerging Therapy, Unmet Needs and TPP Insights: Here's What …
Thelansis releases its Rheumatoid Arthritis (RA) Emerging Therapy, with Unmet Needs and TPP Insights report - 2026, mapping the pipeline, clinical gaps, and target product…
IgA Nephropathy Enters a New Era: Emerging Therapies, Precision Medicine & Unmet …
For a long time, IgA Nephropathy sat in a frustrating category: common enough to matter, complex enough to resist easy solutions. Patients, most of them…
Triple-Negative Breast Cancer Market Outlook & Forecast: ADCs & Immunotherapy Br …
Thelansis, a leading healthcare market research and consulting firm, has published its latest report on "Triple Negative Breast Cancer (TNBC): Market Outlook, Epidemiology, Competitive Landscape,…
HER2-Positive Breast Cancer Market Outlook & Forecast: ADC Innovation & Precisio …
HER2-positive breast cancer remains one of the most biologically aggressive breast cancer subtypes, accounting for approximately 15-20% of all breast cancer cases worldwide. However, the…
Advanced Melanoma Market Forecast 2036: Rising Incidence, Cellular Therapies & P …
Executive Summary
The advanced melanoma treatment landscape is undergoing one of the most significant transformations in oncology, driven by next-generation immunotherapies, the first-ever FDA-approved cellular therapy…
Major Depressive Disorder Market Outlook & Forecast: Novel Mechanisms & Long-Ter …
The MDD treatment landscape is currently undergoing a meaningful transformation. Beyond traditional monoamine-based antidepressants, the market is witnessing growing interest in rapid-acting therapies, NMDA receptor…
Thelansis Publishes Multiple Sclerosis Market Outlook & Forecast: Navigating One …
Thelansis, a leading pharmaceutical intelligence and market research firm, has released its highly anticipated Multiple Sclerosis (MS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast…
NSCLC Market Outlook & Forecast: Precision Oncology, Immunotherapy Innovation, a …
Executive Summary
The global Non-Small Cell Lung Cancer (NSCLC) market is entering a transformative phase driven by rapid advances in precision oncology, biomarker-guided treatment approaches, next-generation…
Charcot-Marie-Tooth (CMT) Market Shift: Emerging Therapies & Unmet Needs Reshapi …
Thelansis launches its Charcot-Marie-Tooth (CMT) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026, offering pharma and biotech decision-makers a clear view of…
Recurrent Respiratory Papillomatosis (RRP) Treatment Enters a New Era, Yet Criti …
Thelansis Releases Its 2026 Recurrent Respiratory Papillomatosis (RRP) Emerging Therapy, Unmet Needs, and TPP Insights Report, Mapping The Competitive Landscape Post-First Approval And What Comes…
Fibrodysplasia Ossificans Progressiva Market Outlook & Forecast: Emerging Pipeli …
Following the first approved disease-modifying therapy and a growing pipeline of ACVR1-targeted treatments, the Fibrodysplasia Ossificans Progressiva (FOP) market is entering a new phase of…
Cutaneous Lupus Erythematosus Market Set for First Targeted Therapy in 70 Years …
For decades, CLE has sat in a strange spot - clinically distinct from systemic lupus, yet treated with the same blunt instruments: corticosteroids, antimalarials, and…
Retinitis Pigmentosa Market Set to Nearly Double by 2034 as Gene Therapies Edge …
Retinitis pigmentosa, a group of inherited retinal disorders that progressively destroy rod and cone photoreceptors, has long left patients with little more than supportive care…
Polycythemia Vera Market Poised for a Paradigm Shift as First-in-Class Hepcidin …
Polycythemia Vera (PV), the most common of the BCR-ABL1-negative myeloproliferative neoplasms, is entering one of its most active periods of therapeutic innovation in decades. With…
Idiopathic Pulmonary Fibrosis Market Outlook & Forecast: Next-Gen Antifibrotics …
Idiopathic Pulmonary Fibrosis (IPF) remains one of respiratory medicine's toughest challenges - a progressive, irreversible scarring of the lungs that still carries a five-year survival…
Thelansis Unveils ADPKD Market Outlook & Forecast, Highlighting Late-Stage Gene …
ADPKD remains one of the most consequential inherited kidney disorders worldwide, affecting an estimated 4 to 6 million people and standing as a leading genetic…
Hidradenitis Suppurativa Market Outlook & Forecast: Rapidly Evolving Treatment & …
The Hidradenitis Suppurativa (HS) market has reached an inflection point, shaped by a wave of recent biologic approvals, compelling late-stage clinical readouts, and a rapidly…
Hypercholesterolemia Market Outlook and Forecast: New Approvals, Evolving Guidel …
Thelansis Knowledge Partners Releases Comprehensive Intelligence Report on the Global Hypercholesterolemia Market covering Epidemiology, Emerging Therapies, Pipeline Dynamics, and 10-Year Commercial Forecasts Across 30+ Countries
As…
Huntington Disease Market Outlook & Forecast: Gene Therapy Advances and Emerging …
EXECUTIVE SUMMARY
Huntington's disease (HD) is no longer a condition that pharmaceutical stakeholders can afford to overlook. Once considered a niche rare neurological disorder, HD is…
Acute Myeloid Leukemia (AML) Market Outlook 2026-2036: Targeted Therapies, Pipel …
Acute Myeloid Leukemia (AML) is no longer the monolithic diagnosis it once was. Over the last decade and especially through 2024 and 2025, genomic science…
Thelansis Unveils Idiopathic Hypersomnia Market Outlook & Forecast, Highlighting …
A sleeping disorder no longer flying under the radar, the IH market is waking up, and the commercial window is widening fast.
Executive Summary
Idiopathic Hypersomnia (IH),…
Hypercholesterolemia Market at a Turning Point: Emerging Therapy, Unmet Needs & …
Thelansis has released its latest market intelligence report, Hypercholesterolemia: Emerging Therapy, Unmet Needs and TPP Insights - 2026, providing a comprehensive view of where the…
Autism Spectrum Disorder Market Outlook & Forecast: Precision Medicine, Pipeline …
Autism Spectrum Disorder (ASD) market poised for significant transformation as precision medicine and digital diagnostics reshape the future of care; in this context, Thelansis releases…
Thelansis Unveils Essential Tremor Market Outlook & Forecast: Pipeline Innovatio …
Thelansis Knowledge Partners has released its latest research report, "Essential Tremor (ET) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 to…
Fabry Disease Market Outlook & Forecast: Classic & Later-Onset Subtypes Drive 20 …
Thelansis Knowledge Partners has published its latest research report, "Fabry Disease (FD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036)", providing a…
Friedreich's Ataxia Market Outlook & Forecast: A 10-Year Framework for the Evolv …
The Friedreich's Ataxia market is no longer a static rare disease space; it's a field in motion. With the first approved disease-specific therapy now anchoring…
Tourette Syndrome Market Outlook & Forecast: 70-80% Genetic Predisposition in Ch …
Thelansis Knowledge Partners has published its latest research report: "Tourette Syndrome (TS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026…
Moderate to Severe Rheumatoid Arthritis Market Outlook & Forecast: Precision Med …
As the RA treatment paradigm shifts from trial-and-error escalation toward precision-driven immunomodulation, Thelansis delivers a definitive 10-year intelligence report covering 31 markets globally.
Thelansis has released…
IgA Nephropathy Market Outlook & Forecast: FDA Approvals and Pipeline Innovation …
IgA Nephropathy (IgAN) has quietly remained the most common primary glomerular disease worldwide and for decades, patients had very little beyond blood pressure control and…
Alzheimer's Disease Market Outlook & Forecast: New Therapies & The Era of Diseas …
Thelansis Knowledge Partners has published its landmark research report: "Alzheimer's Disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 to 2036",…
Metastatic Colorectal Cancer Market Outlook & Forecast: Precision Oncology Resha …
Metastatic colorectal cancer (mCRC) remains one of oncology's most pressing challenges, accounting for approximately 20-25% of all colorectal cancer diagnoses and carrying a five-year survival…
Fibrostenotic Crohn's Disease (FSCD) Market Outlook & Forecast: Thelansis Highli …
Fibrostenotic Crohn's Disease (FSCD) represents one of the most challenging and costly complications of Crohn's disease, where chronic inflammation progresses to irreversible intestinal fibrosis and…
Amyotrophic Lateral Sclerosis (ALS) Market Outlook & Forecast: Precision Medicin …
EXECUTIVE SUMMARY
Amyotrophic Lateral Sclerosis (ALS) remains one of the most devastating and rapidly progressing neurodegenerative diseases known to medicine. Despite decades of research, the disease…
Brain Metastases Market Outlook & Forecast: Evolution of Treatment Options for a …
Thelansis Knowledge Partners has published its latest research report: "Brain Metastasis (BM) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To…
Thelansis' Duchenne Muscular Dystrophy (DMD) Market Outlook and Forecast | Gene …
Thelansis releases a comprehensive Duchenne Muscular Dystrophy (DMD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (2026-2036). The report delivers a 10-year forward-looking…
Prader-Willi Syndrome Market Outlook & Forecast: Thelansis Projects Rising Diagn …
Thelansis Knowledge Partners has released its latest "Prader-Willi Syndrome (PWS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 to 2036," delivering…
Clostridioides Difficile Infection Market Outlook & Forecast: Strategic Insights …
Clostridioides difficile infection (CDI) is entering a new phase of innovation as microbiome therapeutics, targeted antibiotics, and prevention-focused strategies reshape a market long constrained by…
Go To Page: 1
